Haisco Pharmaceutical Group Co., Ltd. (SHE:002653)
China
· Delayed Price · Currency is CNY | Market Cap | 61.57B |
| Revenue (ttm) | 5.06B |
| Net Income (ttm) | 767.58M |
| Shares Out | 1.11B |
| EPS (ttm) | 0.69 |
| PE Ratio | 80.61 |
| Forward PE | 70.27 |
| Dividend | 0.27 (0.48%) |
| Ex-Dividend Date | May 15, 2026 |
| Volume | 6,152,750 |
| Average Volume | 5,410,204 |
| Open | 47.90 |
| Previous Close | 57.10 |
| Day's Range | 47.90 - 59.00 |
| 52-Week Range | 41.72 - 62.65 |
| Beta | -0.18 |
| RSI | 60.53 |
| Earnings Date | Aug 14, 2026 |
About SHE:002653
Haisco Pharmaceutical Group Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in China. It offers pharmaceutical products in the areas of anesthesia and analgesic, endocrine system, enteral parenteral nutrition, cardiovascular, psychiatric, tumor-related, digestive liver, and other diseases. Haisco Pharmaceutical Group Co., Ltd. has licensing and research collaboration with Eli Lilly and Company to develop medicines across multiple therapeutic areas. The company was formerly known as Xizang Haisco Pharmac... [Read more]
Financial Performance
In 2025, SHE:002653's revenue was 4.39 billion, an increase of 17.91% compared to the previous year's 3.72 billion. Earnings were 259.58 million, a decrease of -34.36%.
Financial StatementsNews
Nuvectis gains two experimental drugs in licensing deal with China's Haisco
Nuvectis Pharma said on Monday it had licensed exclusive rights outside China to two experimental drugs from Haisco Pharmaceutical Group , targeting complement-mediated diseases and cancer to broaden ...
Haisco Announces Licensing And Research Collaboration With Lilly
(RTTNews) - Haisco Pharmaceutical Group Co., Ltd. (002653), has entered into a licensing and research collaboration agreement with Eli Lilly and Company (LLY) to develop innovative medicines across mu...
Haisco Pharmaceutical Group Quarterly report: Q1 2026
Haisco Pharmaceutical Group has published its Q1 2026 quarterly earnings report on May 13, 2026.
Haisco Pharmaceutical Group Annual report: Q4 2025
Haisco Pharmaceutical Group has published its Q4 2025 annual report on May 11, 2026.
As China’s biotech firms shift gears, can AI floor the accelerator?
A quarter featuring multiple eye-popping deals is no longer unusual for China’s pharmaceutical industry – in fact, it may soon be considered a slow season. In recent months, companies including CSPC P...
Haisco Pharmaceutical Group Quarterly report: Q3 2025
Haisco Pharmaceutical Group has published its Q3 2025 quarterly earnings report on October 28, 2025.
Haisco Pharmaceutical Group Quarterly report: Q2 2025
Haisco Pharmaceutical Group has published its Q2 2025 quarterly earnings report on August 25, 2025.